RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Cell Therapy as Target Therapy against Colon Cancer Stem Cells.
Cell Therapy as Target Therapy against Colon Cancer Stem Cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
癌症干细胞(CSCs)是肿瘤内一小群具有自我更新、分化和致瘤性等特性的细胞。CSCs被认为是合理的治疗靶点,因为它们负责肿瘤复发、转移和常规治疗耐药。选择性靶向CSCs是一种有前景的策略,可消除肿瘤细胞的增殖并损害整体肿瘤发展。近期研究表明,几种免疫细胞通过调节不同的CSC维持或增殖途径,在调控肿瘤细胞增殖中发挥关键作用。在使用T细胞、自然杀伤(NK)细胞、巨噬细胞或干细胞对结直肠癌(CRC)中的肿瘤细胞或CSCs进行选择性靶向的细胞免疫治疗方面已取得巨大进展。本综述总结了可能从上述治疗中获益的CRC分子特征,以及用于针对CSCs的细胞治疗的主要载体。我们还讨论了在CRC晚期联合常规和/或当前靶向治疗的挑战、局限性和优势。
Cancer stem cells (CSCs) are a small subpopulation of cells within tumors with properties, such as self-renewal, differentiation, and tumorigenicity. CSCs have been proposed as a plausible therapeutic target as they are responsible for tumor recurrence, metastasis, and conventional therapy resistance. Selectively targeting CSCs is a promising strategy to eliminate the propagation of tumor cells and impair overall tumor development.
Recent research shows that several immune cells play a crucial role in regulating tumor cell proliferation by regulating different CSC maintenance or proliferation pathways. There have been great advances in cellular immunotherapy using T cells, natural killer (NK) cells, macrophages, or stem cells for the selective targeting of tumor cells or CSCs in colorectal cancer (CRC). This review summarizes the CRC molecular profiles that may benefit from said therapy and the main vehicles used in cell therapy against CSCs.
We also discuss the challenges, limitations, and advantages of combining conventional and/or current targeted treatments in the late stages of CRC.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。